Search
Nerandomilast
go.drugbank.com/drugs/DB18237ApprovedInvestigational[L54858] In the Phase 3 FIBRONEER-ILD trial, nerandomilast led to a smaller decline in forced vital capacity (FVC) than placebo over 52 weeks. [A274591] … [L54126] On October 7, 2025, nerandomilast was approved as the first new treatment for idiopathic pulmonary fibrosis in more than a decade.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsRimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigationalsafer for use in patients with contraindications to standard therapy. … [L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and
Categories: MATE 1 Inhibitors, P-glycoprotein substratesAmiloride
go.drugbank.com/drugs/DB00594ApprovedInvestigationalThis inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. … Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss.
Mixtures: PLENACOR D, MODURETIC® TABLETASCategories: Acid Sensing Ion Channel Blockers, Decreased Renal K+ ExcretionGlasdegib
go.drugbank.com/drugs/DB11978ApprovedInvestigationalCurrently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due … In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsBuformin
go.drugbank.com/drugs/DB04830ApprovedWithdrawnIt was withdrawn from the market in most countries due to a high risk of causing lactic acidosis. … Buformin is an anti-diabetic drug of the biguanide class, chemically related to metformin and phenformin.
Categories: Drugs Used in DiabetesSynonyms: 1-ButylbiguanideEladocagene exuparvovec
go.drugbank.com/drugs/DB16780ApprovedInvestigationaland rare genetic disorder that causes severe disability in pediatric patients. … By promoting the expression of AADC, eladocagene exuparvovec leads to the development of motor function in patients with AADC deficiency.
Categories: Genetic TherapyAtractylodes lancea root oil
go.drugbank.com/drugs/DB14338ApprovedAtractylodes lancea root oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Mixtures: O Hui White Extreme Blemish Balm, The History Of Whoo Gongjinhyang Seol Whitening SunHomatropine
go.drugbank.com/drugs/DB11181ApprovedIt is present in antitussives, under the trade name Hycodan, in combination with hydrocodone (dihydrocodeinone) bitartrate indicated for the symptomatic relief of cough as oral tablets or solutions. … Homatropine is included in subtherapeutic amounts as homatropine methylbromide to discourage deliberate overdosage.
Products: HOMATRO 2%, Isopto Homatropine 2%Atrasentan
go.drugbank.com/drugs/DB06199ApprovedInvestigational[L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist … Atrasentan is a novel, selective endothelin A receptor antagonist (SERA).
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitorsSeladelpar
go.drugbank.com/drugs/DB12390ApprovedInvestigationalSeladelpar is a peroxisome proliferator-activated receptor (PPAR)-delta (δ) agonist. Seladelpar is a single enantiomer of the R-configuration. … [L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSynonyms: (R)-2-(4-((2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)-THIO)-2-METHYLPHENOXY)ACETIC ACID, ((4-(((2R)-2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)THIO)-2-METHYLPHENYL)OXY)ACETIC ACID